Understand the source comparison
Comparison: AOD-9604 vs 5-Amino-1MQ — Mechanisms and Research Use
AOD-9604 Stimulates hormone-sensitive lipase (HSL) to hydrolyze triglycerides into free fatty acids White adipose tissue (beta-3 adrenergic receptors) Increased lipolysis without glucose or IGF-1 changes; fat mobilization independent of caloric deficit 250–500
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AOD-9604
- Stimulates hormone-sensitive lipase (HSL) to hydrolyze triglycerides into free fatty acids
- White adipose tissue (beta-3 adrenergic receptors)
- Increased lipolysis without glucose or IGF-1 changes; fat mobilization independent of caloric deficit
- 250–500 mcg subcutaneously per administration
- Best for isolating adipocyte breakdown as an independent variable. Models fat release without systemic hormonal disruption
- 5-Amino-1MQ
- Inhibits NNMT to prevent NAD+ depletion, increasing mitochondrial oxidative capacity
- Adipose and hepatic tissue
- Increased NAD+ (20–30%), enhanced fatty acid oxidation, improved insulin sensitivity
- 25–50 mg orally per administration
- Best for studying metabolic rewiring. Tests whether NAD+ restoration alone can shift energy partitioning without appetite or thyroid modulation
- Combined Use
- Dual-pathway targeting: lipolysis stimulation + oxidative capacity restoration
- Adipocytes and mitochondria
- Synergistic fat reduction (15–20% greater than additive effects), reduced re-esterification of mobilized fatty acids
- Both at research dosage ranges
- Models whether addressing mobilization and oxidation simultaneously overcomes fat-loss resistance better than single-pathway interventions